ATRA
Price:
$9.62
Market Cap:
$86.68M
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic ma...[Read more]
Industry
Biotechnology
IPO Date
2014-10-16
Stock Exchange
NASDAQ
Ticker
ATRA
According to Atara Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.89. This represents a change of 42.78% compared to the average of -5.53 of the last 4 quarters.
The mean historical PE Ratio of Atara Biotherapeutics, Inc. over the last ten years is -0.95. The current -7.89 PE Ratio has changed 82.99% with respect to the historical average. Over the past ten years (40 quarters), ATRA's PE Ratio was at its highest in in the June 2022 quarter at 10.82. The PE Ratio was at its lowest in in the December 2025 quarter at -16.66.
Average
-0.95
Median
-0.91
Minimum
-4.74
Maximum
6.94
Discovering the peaks and valleys of Atara Biotherapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 493.31%
Maximum Annual PE Ratio = 6.94
Minimum Annual Increase = -694.86%
Minimum Annual PE Ratio = -4.74
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | 6.94 | -694.86% |
| 2024 | -1.17 | 493.31% |
| 2023 | -0.20 | -86.58% |
| 2022 | -1.47 | -66.24% |
| 2021 | -4.34 | -8.36% |
| 2020 | -4.74 | 63.07% |
| 2019 | -2.90 | 340.20% |
| 2018 | -0.66 | 45.84% |
| 2017 | -0.45 | -12.36% |
| 2016 | -0.52 | -56.29% |
The current PE Ratio of Atara Biotherapeutics, Inc. (ATRA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
1.86
5-year avg
-0.05
10-year avg
-0.95
Atara Biotherapeutics, Inc.’s PE Ratio is less than Ovid Therapeutics Inc. (-7.20), greater than Shattuck Labs, Inc. (-9.74), less than Context Therapeutics Inc. (-1.54), less than MacroGenics, Inc. (-3.50), greater than Champions Oncology, Inc. (-41.89), less than Oramed Pharmaceuticals Inc. (1.40), less than Sutro Biopharma, Inc. (-0.02), less than InflaRx N.V. (-2.32), less than Coya Therapeutics, Inc. (-3.82), less than Clene Inc. (-2.03),
| Company | PE Ratio | Market cap |
|---|---|---|
| -7.20 | $311.25M | |
| -9.74 | $207.42M | |
| -1.54 | $59.75M | |
| -3.50 | $246.62M | |
| -41.89 | $95.54M | |
| 1.40 | $154.29M | |
| -0.02 | $272.61M | |
| -2.32 | $115.57M | |
| -3.82 | $87.77M | |
| -2.03 | $60.30M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Atara Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Atara Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Atara Biotherapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Atara Biotherapeutics, Inc. (ATRA)?
What is the highest PE Ratio for Atara Biotherapeutics, Inc. (ATRA)?
What is the 3-year average PE Ratio for Atara Biotherapeutics, Inc. (ATRA)?
What is the 5-year average PE Ratio for Atara Biotherapeutics, Inc. (ATRA)?
How does the current PE Ratio for Atara Biotherapeutics, Inc. (ATRA) compare to its historical average?